Newman Dignan & Sheerar Inc’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,522	Closed	-$18.8K	–	198
2023 Q1	$18.8K	Hold	12,522	–	–	0.01%	191
2022 Q4	$12.5K	Buy	12,522 +1,000	+9%	+$1.35K	﹤0.01%	188
2022 Q3	$21	Buy	+11,522	New	+$33.4K	﹤0.01%	179
2022 Q2	–	Sell	-11,023	Closed	-$30	–	211
2022 Q1	$30	Buy	+11,023	New	+$34.7K	0.01%	192

Newman Dignan & Sheerar Inc's TCRR Position: Q2 2023 in Review

Newman Dignan & Sheerar Inc sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 12,522 shares — an estimated $18.8K sold.

Newman Dignan & Sheerar Inc first reported a position in TCRR in Q1 2022 and held it in 4 quarters. The position peaked at $18.8K in Q1 2023. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Newman Dignan & Sheerar Inc reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Newman Dignan & Sheerar Inc sold 12,522 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $18.8K.
Newman Dignan & Sheerar Inc first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Newman Dignan & Sheerar Inc's TCR2 Therapeutics Inc. Common Stock position peaked at $18.8K in Q1 2023.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q2 2023, filed 2 Aug 2023.